AAPL343.91-3.82 (-1.10%) ▼|ABBV286.74+1.10 (+0.39%) ▲|ABT104.88+1.18 (+1.14%) ▲|ACN247.23-2.14 (-0.86%) ▼|ADBE258.62-5.20 (-1.97%) ▼|AMAT387.59+10.35 (+2.74%) ▲|AMD531.28+14.49 (+2.80%) ▲|AMGN444.63+5.37 (+1.22%) ▲|AMT188.28-0.69 (-0.37%) ▼|AMZN249.09+1.09 (+0.44%) ▲|AVGO329.17+7.49 (+2.33%) ▲|AXP315.05+1.83 (+0.58%) ▲|BA188.31-0.04 (-0.02%) ▼|BAC50.52-0.04 (-0.08%) ▼|BKNG153.14-2.69 (-1.73%) ▼|BLK1,127.66+9.41 (+0.84%) ▲|BMY61.61+0.13 (+0.21%) ▲|BNY147.18+2.54 (+1.76%) ▲|BRK-B548.56+6.37 (+1.17%) ▲|C121.04+0.42 (+0.35%) ▲|CAT692.13+6.76 (+0.99%) ▲|CL93.10-0.94 (-1.00%) ▼|CMCSA22.05-0.64 (-2.82%) ▼|COF202.35+1.01 (+0.50%) ▲|COP151.37+0.57 (+0.38%) ▲|COST1,005.16+1.84 (+0.18%) ▲|CRM247.61-0.96 (-0.39%) ▼|CSCO110.24+3.74 (+3.51%) ▲|CVS92.53-0.94 (-1.01%) ▼|CVX232.01-1.20 (-0.51%) ▼|DE641.25-4.90 (-0.76%) ▼|DHR232.97+2.47 (+1.07%) ▲|DIS110.40-2.12 (-1.88%) ▼|DUK124.44-0.54 (-0.43%) ▼|EMR161.70+0.11 (+0.07%) ▲|FDX300.58+1.86 (+0.62%) ▲|GD357.04+7.68 (+2.20%) ▲|GE288.43+2.79 (+0.98%) ▲|GEV855.12+40.12 (+4.92%) ▲|GILD158.69+2.65 (+1.70%) ▲|GM76.31+0.39 (+0.51%) ▲|GOOG314.19-3.09 (-0.97%) ▼|GOOGL316.80-3.41 (-1.06%) ▼|GS893.28+17.60 (+2.01%) ▲|HD319.38-0.45 (-0.14%) ▼|HON219.28-1.87 (-0.85%) ▼|IBM253.44-0.12 (-0.05%) ▼|INTC90.47+3.51 (+4.04%) ▲|INTU339.89-3.50 (-1.02%) ▼|ISRG451.63-0.66 (-0.15%) ▼|JNJ266.30+2.49 (+0.94%) ▲|JPM334.04+2.46 (+0.74%) ▲|KO92.70-0.01 (-0.01%) ▼|LIN507.56-1.27 (-0.25%) ▼|LLY1,279.14+5.68 (+0.45%) ▲|LMT635.20+31.02 (+5.13%) ▲|LOW198.22-0.46 (-0.23%) ▼|LRCX237.50+7.40 (+3.22%) ▲|MA613.50-10.10 (-1.62%) ▼|MCD250.83+2.37 (+0.95%) ▲|MDLZ62.97-0.83 (-1.30%) ▼|MDT94.79-0.62 (-0.65%) ▼|META630.56-12.06 (-1.88%) ▼|MMM172.79-0.67 (-0.39%) ▼|MO73.62-0.69 (-0.93%) ▼|MRK140.61-4.66 (-3.21%) ▼|MS183.49+4.00 (+2.23%) ▲|MSFT532.60+8.09 (+1.54%) ▲|MU903.70+26.15 (+2.98%) ▲|NEE82.04-0.06 (-0.07%) ▼|NFLX63.90-1.95 (-2.96%) ▼|NKE37.91+0.61 (+1.64%) ▲|NOW158.18-0.78 (-0.49%) ▼|NVDA216.00+5.04 (+2.39%) ▲|ORCL126.06-0.10 (-0.08%) ▼|PEP135.46-0.31 (-0.23%) ▼|PFE29.79-0.24 (-0.80%) ▼|PG159.92-1.10 (-0.68%) ▼|PLTR198.84+2.09 (+1.06%) ▲|PM201.87+2.40 (+1.20%) ▲|QCOM179.60+3.69 (+2.10%) ▲|RTX197.48+6.47 (+3.39%) ▲|SBUX102.69+1.89 (+1.88%) ▲|SCHW89.73-0.85 (-0.94%) ▼|SO92.57-0.32 (-0.34%) ▼|SPG212.69+1.06 (+0.50%) ▲|T20.85-0.08 (-0.38%) ▼|TMO684.89+11.07 (+1.64%) ▲|TMUS146.93+0.39 (+0.27%) ▲|TSLA391.62+19.40 (+5.21%) ▲|TXN298.12+13.43 (+4.72%) ▲|UBER66.13-0.57 (-0.85%) ▼|UNH410.70-7.39 (-1.77%) ▼|UNP296.97+4.10 (+1.40%) ▲|UPS100.32-0.74 (-0.73%) ▼|USB59.70+0.12 (+0.20%) ▲|V404.16-3.76 (-0.92%) ▼|VZ43.10-1.56 (-3.49%) ▼|WFC82.65+0.26 (+0.32%) ▲|WMT120.29+0.40 (+0.33%) ▲|XOM184.54+1.33 (+0.73%) ▲|AAPL343.91-3.82 (-1.10%) ▼|ABBV286.74+1.10 (+0.39%) ▲|ABT104.88+1.18 (+1.14%) ▲|ACN247.23-2.14 (-0.86%) ▼|ADBE258.62-5.20 (-1.97%) ▼|AMAT387.59+10.35 (+2.74%) ▲|AMD531.28+14.49 (+2.80%) ▲|AMGN444.63+5.37 (+1.22%) ▲|AMT188.28-0.69 (-0.37%) ▼|AMZN249.09+1.09 (+0.44%) ▲|AVGO329.17+7.49 (+2.33%) ▲|AXP315.05+1.83 (+0.58%) ▲|BA188.31-0.04 (-0.02%) ▼|BAC50.52-0.04 (-0.08%) ▼|BKNG153.14-2.69 (-1.73%) ▼|BLK1,127.66+9.41 (+0.84%) ▲|BMY61.61+0.13 (+0.21%) ▲|BNY147.18+2.54 (+1.76%) ▲|BRK-B548.56+6.37 (+1.17%) ▲|C121.04+0.42 (+0.35%) ▲|CAT692.13+6.76 (+0.99%) ▲|CL93.10-0.94 (-1.00%) ▼|CMCSA22.05-0.64 (-2.82%) ▼|COF202.35+1.01 (+0.50%) ▲|COP151.37+0.57 (+0.38%) ▲|COST1,005.16+1.84 (+0.18%) ▲|CRM247.61-0.96 (-0.39%) ▼|CSCO110.24+3.74 (+3.51%) ▲|CVS92.53-0.94 (-1.01%) ▼|CVX232.01-1.20 (-0.51%) ▼|DE641.25-4.90 (-0.76%) ▼|DHR232.97+2.47 (+1.07%) ▲|DIS110.40-2.12 (-1.88%) ▼|DUK124.44-0.54 (-0.43%) ▼|EMR161.70+0.11 (+0.07%) ▲|FDX300.58+1.86 (+0.62%) ▲|GD357.04+7.68 (+2.20%) ▲|GE288.43+2.79 (+0.98%) ▲|GEV855.12+40.12 (+4.92%) ▲|GILD158.69+2.65 (+1.70%) ▲|GM76.31+0.39 (+0.51%) ▲|GOOG314.19-3.09 (-0.97%) ▼|GOOGL316.80-3.41 (-1.06%) ▼|GS893.28+17.60 (+2.01%) ▲|HD319.38-0.45 (-0.14%) ▼|HON219.28-1.87 (-0.85%) ▼|IBM253.44-0.12 (-0.05%) ▼|INTC90.47+3.51 (+4.04%) ▲|INTU339.89-3.50 (-1.02%) ▼|ISRG451.63-0.66 (-0.15%) ▼|JNJ266.30+2.49 (+0.94%) ▲|JPM334.04+2.46 (+0.74%) ▲|KO92.70-0.01 (-0.01%) ▼|LIN507.56-1.27 (-0.25%) ▼|LLY1,279.14+5.68 (+0.45%) ▲|LMT635.20+31.02 (+5.13%) ▲|LOW198.22-0.46 (-0.23%) ▼|LRCX237.50+7.40 (+3.22%) ▲|MA613.50-10.10 (-1.62%) ▼|MCD250.83+2.37 (+0.95%) ▲|MDLZ62.97-0.83 (-1.30%) ▼|MDT94.79-0.62 (-0.65%) ▼|META630.56-12.06 (-1.88%) ▼|MMM172.79-0.67 (-0.39%) ▼|MO73.62-0.69 (-0.93%) ▼|MRK140.61-4.66 (-3.21%) ▼|MS183.49+4.00 (+2.23%) ▲|MSFT532.60+8.09 (+1.54%) ▲|MU903.70+26.15 (+2.98%) ▲|NEE82.04-0.06 (-0.07%) ▼|NFLX63.90-1.95 (-2.96%) ▼|NKE37.91+0.61 (+1.64%) ▲|NOW158.18-0.78 (-0.49%) ▼|NVDA216.00+5.04 (+2.39%) ▲|ORCL126.06-0.10 (-0.08%) ▼|PEP135.46-0.31 (-0.23%) ▼|PFE29.79-0.24 (-0.80%) ▼|PG159.92-1.10 (-0.68%) ▼|PLTR198.84+2.09 (+1.06%) ▲|PM201.87+2.40 (+1.20%) ▲|QCOM179.60+3.69 (+2.10%) ▲|RTX197.48+6.47 (+3.39%) ▲|SBUX102.69+1.89 (+1.88%) ▲|SCHW89.73-0.85 (-0.94%) ▼|SO92.57-0.32 (-0.34%) ▼|SPG212.69+1.06 (+0.50%) ▲|T20.85-0.08 (-0.38%) ▼|TMO684.89+11.07 (+1.64%) ▲|TMUS146.93+0.39 (+0.27%) ▲|TSLA391.62+19.40 (+5.21%) ▲|TXN298.12+13.43 (+4.72%) ▲|UBER66.13-0.57 (-0.85%) ▼|UNH410.70-7.39 (-1.77%) ▼|UNP296.97+4.10 (+1.40%) ▲|UPS100.32-0.74 (-0.73%) ▼|USB59.70+0.12 (+0.20%) ▲|V404.16-3.76 (-0.92%) ▼|VZ43.10-1.56 (-3.49%) ▼|WFC82.65+0.26 (+0.32%) ▲|WMT120.29+0.40 (+0.33%) ▲|XOM184.54+1.33 (+0.73%) ▲|
17.7 C
New York
Tuesday, October 27, 2026

Tag: progress

newsFORsourcecompanycontentinformation1releasesmarket

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase...

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of...

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of...

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor,...

New data on Lilly’s investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant...

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 25, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma")  will publish the phase...

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 24, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma")  will publish the phase...

In HelloNation, Behavioral Health Experts Cody Luke and David Spencer Explain What to Expect During Your First Therapy Session

The article outlines how first sessions build understanding, set goals, and support a comfortable start to therapy.IDAHO FALLS, Idaho, Oct. 24, 2026 /PRNewswire/ --...

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than TripledLate-Breaking Phase 3 DeLLphi-305 Results Presented in...

The Galien Foundation Presents Senator John Kerry with 2026 Roy Vagelos Pro Bono Humanum Award for Global Health Equity

Honoring the former U.S. Secretary of State and Special Presidential Envoy for Climate for pioneering efforts to address climate change and public health initiativesAward...

mF International to Wind Down Legacy Financial Trading Business, Shift Focus Completely to Digital Asset Strategy

Strategic decision allows the Company to commit its full energy to a growing digital asset-centric business modelmF International holds 678,922 Bitcoin Cash (BCH) as...

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie’s SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn’s Disease

Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the...

UCB Establishes the Emmanuel Janssen Endowed Chair for the Evaluation of Medicines at Brigham and Women’s Hospital

Permanent endowment advances pharmacoepidemiology and real-world evidence researchSebastian Schneeweiss, MD, ScD, an internationally recognized pharmacoepidemiologist whose research focuses on improving medication safety, effectiveness, and...

Novo’s Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes

Awiqli® offers children 10 years and older a once-weekly basal insulin alternative, reducing basal injection frequency from seven times per week to one1As type 2...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProgress

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers